Clinical Trial Update: Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects [Phase 2]

View source ↗

Summary

Phase 2 study of ABT-267 in treatment-naive hepatitis C virus genotype 1 infection completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-267

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26